BIOT-YG-I FIA Analyzer (Fluorescence Immunoassay Analyzer)

The ALL NEW FLI-100 Analyser represents an elevated standard at Biotime, in pursuing simplicity, quality assurance, and data security for healthcare organizations. Designed for quantitative in vitro assay determinations, the Biotime FLI-100 analyser was purposefully built to support immunoassay analysis for a broad range of applications – from biomarker work to infectious disease testing. The analyser’s immunofluorescence technology yields high sensitivity, reliable, and reproducible results for convenient point-of-care diagnostic testing on one device with a small footprint.

The incubation chamber is an auxiliary device for Biotime’s fluorescence immunoassay analyzer. The reaction temperature and time is critical for test results. The incubation chamber provides an optimized environment as well as automatic timers for test reactions to improve the reliability of test results.

FLI-600 is a fluorescent immunoassay system with 6 channels that uses blood and urine to measure the quantitative concentration of targeted analyte. Its automated test process enables to carry out multiple simultaneous tests for six different samples.

FLI-4000 is an automatic immunoassay analyzer that measures the concentration of targeted analyte in human blood and urine. FLI-4000 is designed for processing / analyzing large volumes of samples and can carry up to 40 tests per hour (depending on the type of item).

PCT(Procalcitonin) is a peptide precursor of the hormone calcitonin. Measurement of PCT can be used as an authoritative marker for diagnosis and stratification of sepsis.

NT-proBNP is a marker for detecting heart function, with a long half-life and high specificity. Biotime NT-proBNP test kit detects the amount of NT-proBNP in human whole blood, serum and plasma samples.

The SARS-CoV-2 Antigen Rapid Qualitative Test is a colloidal gold immunochromatography intended for the qualitative detection of nucleocapsid antigens from SARS-CoV-2 in human nasal swabs, throat swabs, and sputum from individuals who are suspected of COVID-19 by their healthcare provider. within the first five days of the onset of symptoms.

TheCMV IgG/IgM Rapid Test is an in vitro immunoassay for the in vitro qualitative determination of IgG and IgM class antibodies toCMV in human serum. IgG results with this assay are used to indicate past or recent infection with CMV. IgM results obtained with this assay are used as an aid in the diagnosis of acute or recent CMV infections. CMV IgM test shall not be used for prenatal screening of asymptomatic people, and the test results of this reagent shall not be used alone as the basis for termination of pregnancy. -Fluorescent immunoassay -Cytomegalovirus (CMV) infection -For in vitro diagnostic use only. For professional use only.